Scarica l'app Stockscreener
2.75
0.36%
-0.010
Dopo l'orario di chiusura:
2.80
0.05
+1.82%
Okyo Pharma Limited Borsa (OKYO) Ultime notizie
OKYO Pharma Limited Stock Analysis and ForecastMarket-beating returns - PrintWeekIndia
What analysts say about OKYO Pharma Limited stockMassive stock growth - PrintWeekIndia
Will OKYO Pharma Limited stock benefit from AI tech trendsExplosive market performance - jammulinksnews.com
What institutions are buying OKYO Pharma Limited stock nowConsistently exceptional gains - jammulinksnews.com
OKYO Pharma reports promising phase 2 results for urcosimod in neuropathic corneal pain - Pharmafile
What drives OKYO Pharma Limited stock priceAccelerated wealth expansion - Autocar Professional
Is OKYO Pharma Limited a good long term investmentPhenomenal trading returns - Autocar Professional
OKYO Pharma Secures $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain - VisionMonday.com
OKYO Pharma CEO details positive results from Phase 2 urcosimod trialICYMI - Proactive financial news
OKYO Pharma Secures $1.9M Non-Dilutive Funding to Advance Urcosimod Development - AInvest
OKYO Pharma announces positive results from phase 2 trial of urcosimod for neuropathic corneal pain - Ophthalmology Times
OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding - GlobeNewswire
OKYO Pharma receives $1.9 million non-dilutive funding for lead drug development - Investing.com Nigeria
Small cap wrap: Digi Power X, American Resources, OKYO Pharma, Lisata Therapeutics... - Proactive financial news
OKYO Slides Despite Fresh R&D Funding - Baystreet.ca
OKYO Pharma secures $1.9 million in non-dilutive funding for eye drug - Investing.com Canada
Okyo Pharma Obtains $1.9 Million Non-Dilutive Funding - MarketScreener
OKYO Pharma Secures $1.9 Million to Boost Urcosimod Development - TipRanks
OKYO Pharma bolsters ocular pain program with $1.9M non-dilutive financing - Proactive financial news
OKYO Pharma secures $1.9 million in non-dilutive funding for eye drug By Investing.com - Investing.com South Africa
OKYO’s Market Whiplash: 86.16% YTD Rise, -1.66% Plunge in 30 Days - investchronicle.com
OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain - MarketScreener
OKYO Secures $1.9M to Fast-Track Revolutionary Eye Pain Drug with No Current FDA Treatment - Stock Titan
OKYO Pharma stock maintains Buy rating at H.C. Wainwright on positive trial data By Investing.com - Investing.com South Africa
OKYO Pharma stock maintains Buy rating at H.C. Wainwright on positive trial data - Investing.com Australia
OKYO Pharma Limited Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain - MarketScreener
OKYO Pharma Receives Positive Buy Rating from H.C. Wainwright - AInvest
Positive Buy Rating for OKYO Pharma Driven by Promising Phase 2 Trial Results and FDA Fast Track Designation - TipRanks
0.97%
0.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):